Introducing The Ritz-Carlton Residences, Muskoka: A Rare Opportunity to Own Pristine Waterfront Property in a World-Renowned Destination
With only 32 architecturally distinct homes this private sanctuary, The Ritz-Carlton Residences, Muskoka are designed for those seeking the most precious luxury of all: time. Here, nature takes the lead, with each residence blending seamlessly into the land —supported by the legendary service and distinctive luxury of The Ritz-Carlton.
A mainland Homeowner Residence Club—just a short boat ride away via dedicated chauffeur—provides a gathering place for wellness, activity, and connection throughout the seasons.
The design, led by Tucson-based Studio Caban and Copenhagen's Norm Architects, is rooted in restraint and refinement. Timeless Scandinavian minimalism meets Canadian materiality—stone, light, wood, and water—in an architectural language that speaks softly but stays with you.
The residences are offered in layouts ranging from four to eight bedrooms, thoughtfully planned for multi-generational living and weekend guests. Each lot can accommodate multiple detached guest homes, creating private cabins with their own bedrooms, lounges, ensuites, and sweeping water views.
With expansive windows framing the surrounding forest and water, each home opens fully to the elements. Local granite, river stone, and wide-plank hardwoods root the interiors in place. Spacious lots offer total seclusion, while refined individual boathouses over the water provide instant access to lake life. Island trails with elevated lookouts invite slow wandering and quiet reflection or even a morning jog—while cliffs offer exhilarating plunges into the deep, clean water below. In late summer, the forest floor yields sweet wild blueberries—Muskoka's quiet luxury, savored steps from the front door.
Back on the mainland, the Homeowner Residence Club offers a full suite of curated amenities: a Nordic-inspired spa, tennis and pickleball courts, an archery range, indoor golf simulator and mountain bike trails carved through the trees. Children can explore a whimsical treehouse while adults enjoy private training, chef services, and grocery delivery to their docks. A communal fire pit brings neighbors together under the stars—an invitation to slow evenings, shared stories, and lasting connection.
A wine cellar and working greenhouse offer fresh herbs, while eggs, honey and rustic sourdough – all produced onsite —are ready upon arrival. A reimagined barn has been transformed into a serene, light-filled studio for yoga, pilates, and casual community connection—spaces where wellbeing feels woven into the routine.
For over a century, Muskoka has drawn generations seeking simplicity, reflection, and renewal. This offering continues that tradition—not by adding to it, but by distilling it. Sarah Khalifa, Vice President of Mixed-Use Development, Marriott International stated: "This project beautifully integrates luxury living with the stunning natural landscape, creating a harmonious blend that truly captures the essence of Muskoka's beauty. We are thrilled to be on this exciting journey with Density Group Limited as we see our joined vision unfold in such a breathtaking setting." Environmental stewardship is a cornerstone of the project: one-third of the island is permanently protected as conservation land, while surrounding waters are preserved to support fish habitat.
Ownership opportunities are limited. The Ritz-Carlton Residences, Muskoka are coming soon, with private showings starting summer 2025. To explore availability and scheduled site visits please contact The Ritz-Carlton Residences, Muskoka sales team at:
1 (800) 482-0355
+1 (705) 482-0402
www.RCMuskoka.ca
About Hazelton Real Estate:
Hazelton Real Estate proudly represents exciting new development projects in Ontario, Canada. Purchasers searching for personalized services and access to the most exciting residences realize that Hazelton will introduce properties not found elsewhere in the general market.
About Density Group Limited:
Density Group is a privately held real estate firm based in Toronto, known for successfully leading complex projects from concept to completion. With a strong portfolio of land development deals across Canada, the U.S., and Europe, the firm operates through both private equity and strategic debt placement. Its reputation is built on consistent, on-time delivery, a design-driven philosophy, and the enduring trust of its investors. The Ritz-Carlton Residences, Muskoka is the firm's signature legacy project.
The Ritz-Carlton Residences, Muskoka are not owned, developed, promoted or sold by Marriott International, Inc. or its affiliates ("Marriott"). Langmaids Island Corp. uses The Ritz-Carlton marks under a license from Ritz-Carlton, which has not confirmed the accuracy of any of the statements or representations made herein.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
25 minutes ago
- Cision Canada
Airway Therapeutics Receives European Medicines Agency Pediatric Committee Approval for Zelpultide Alfa's Study Plan in Bronchopulmonary Dysplasia for Very Preterm Infants
Multinational Phase 2b dose selection and Phase 3 expansion study for zelpultide alfa set to begin in late Q3/Q4 2025 MARIETTA, Ga., Aug. 12, 2025 /CNW/ -- Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for its investigational biologic, zelpultide alfa, in its initial indication for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants born between 22 and 27 weeks gestational age. Zelpultide alfa is a first-in-class recombinant human surfactant protein D (rhSP-D) designed to modulate immune responses to reduce inflammation, enhance pathogen clearance, and support surfactant homeostasis for improved lung function. "We are pleased to have reached agreement with the PDCO on the Pediatric Investigation Plan and pivotal study design for zelpultide alfa, a ground-breaking therapy being developed to prevent BPD in very preterm infants, a highly vulnerable population with no approved preventative treatments," said Dr. Marc Salzberg, Chairman, Chief Executive & Medical Officer of Airway Therapeutics. "This marks a significant milestone in advancing a potential first-in-class preventive therapy to improve outcomes for these fragile infants and address a critical unmet medical need." The approved PIP includes the design and execution plan for a pivotal Phase 2b/3 clinical trial. The Phase 2b trial will evaluate two different dose levels of zelpultide alfa administered for up to seven days, compared to placebo. Following completion of treatment in 150 patients (50 per arm), one dose will be selected for continuation into Phase 3, during which approximately 216 additional patients will be enrolled. As part of the study, Airway Therapeutics will assess a three-day consecutive BPD evaluation endpoint, which may contribute to the development of improved outcome measures during the studies. "Bronchopulmonary dysplasia remains one of the most challenging complications in neonatal intensive care, with long-term consequences for respiratory and neurodevelopmental outcomes," said Dr. Daniele De Luca, Principal Investigator of the trial and Professor of Pediatrics (Neonatology) at Paris Saclay University. "Zelpultide alfa represents a novel and scientifically promising approach, grounded in our understanding of immune modulation and tissue injury. This study will allow us to rigorously evaluate its potential to change clinical practice by addressing the root drivers of lung injury in very preterm infants." Airway Therapeutics plans to submit the PDCO-approved protocol immediately to health authorities in Italy (AIFA), Spain (AEMPS), and Israel (MoH), with the objective of initiating the clinical trial in these countries in late Q3 or Q4 2025. Additional submissions will follow in France, Germany, Belgium, and Poland, along with planned regulatory filings in Argentina, Australia, and the United States. About Zelpultide Alfa Zelpultide alfa is a recombinant human surfactant protein D (rhSP-D) precisely engineered to replicate the native protein's full quaternary structure and biological function, incorporating optimized glycosylation through advanced cell line technology. Its therapeutic activity is driven by three key mechanisms: modulation of immune responses to mitigate excessive inflammation, enhancement of pathogen recognition and clearance, and maintenance of surfactant homeostasis to support pulmonary function. As a versatile biologic platform, zelpultide alfa is being developed for patients across all age groups—from preventing bronchopulmonary dysplasia (BPD) in very preterm infants to treating acute and chronic respiratory, inflammatory and infectious conditions in adults. Zelpultide alfa's lead indication, BPD prevention, is currently progressing through a pivotal Phase 2b/3 clinical trial, following Phase 1 study that demonstrated a favorable safety and tolerability profile. About Airway Therapeutics Airway Therapeutics is a clinical-stage biopharmaceutical company developing a new class of biologic therapies to redefine the prevention and treatment of respiratory, inflammatory, and infectious diseases. Its lead candidate, zelpultide alfa, is currently in late-stage clinical development for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants, a condition with no approved preventive therapies. As a platform biologic, zelpultide alfa is also being advanced for broader application across age groups and disease settings, with the goal of improving outcomes for vulnerable patient populations. Company Contact: Libba Muzi Airway Therapeutics [email protected] 513-770-9630 Media Contact: Tony Russo, Ph.D. Russo Partners, LLC [email protected] 212-845-4251 SOURCE Airway Therapeutics
Cision Canada
25 minutes ago
- Cision Canada
BarrierBreak Recognized in 2025 Gartner® Market Guide for Digital Accessibility
MUMBAI, India, Aug. 12, 2025 /CNW/ -- BarrierBreak, a global leader in digital accessibility solutions, is proud to be included as Representative Vendor in the 2025 Gartner ® Market Guide for Digital Accessibility. We believe that this recognition highlights BarrierBreak's unique ability to deliver scalable, human-centric digital accessibility solutions that is driven by technology and perfected by experts through its AI-powered platforms. With a vision of advancing the digital landscape to enable experience for disabled people, BarrierBreak believes that accessibility should be integral, inclusive, and impactful. In our opinion, the company's inclusion in this year's Gartner's Market Guide reflects its leadership in creating inclusive digital ecosystems that go beyond checklists. It focuses on prioritizing empathy, usability, and compliance across web, mobile, and document accessibility. " We believe Gartner's recognition affirms our 'human-first' philosophy, where the insight and empathy of human experts are amplified by the speed and scale of automation and AI," said Shilpi Kapoor, Founder and CEO of BarrierBreak. "At BarrierBreak we believe, it's not just about being compliant, but it's about ensuring digital experiences are truly inclusive and usable for all." The 2025 Market Guide, states: 'Today's platforms are increasingly intelligent, proactive and enterprise-grade, offering a blend of automation, AI-enhanced insights and human-centered tooling that helps organizations operationalize accessibility across the full software development life cycle.' – Gartner Market Guide for Digital Accessibility, 2025 Established on the principles of combining technology and workforce diversity, BarrierBreak employs a team where approximately 40% of members are people with disabilities and serve clients across 14 countries. BarrierBreak empowers businesses to ensure compliance with regulations like WCAG, ADA, EAA, and Section 508, while also embedding accessibility into the software development lifecycle. Managing Accessibility with The A11yNow Platform At the core of BarrierBreak's strategy is the A11yNow Platform, which helps companies manage accessibility conformance of their digital assets. A11yNow combines automated scanning, detailed issue tracking and AI to provide support to implement accessibility. It offers advanced rulesets to reduce false positives, assigns specific issues to developers or designers, and includes a help desk feature enabling direct access to assistive tech experts and manual screen-reader testing. This model aligns with Gartner's findings that in the real-world usability testing, though AI enhances automation and detection, it cannot fully replace the nuanced judgment that human experts bring. Key Capabilities of BarrierBreak Since 20 years, BarrierBreak has offered end-to-end digital accessibility services designed to meet the diverse needs of organizations across industries: Manual and Automated audits Web, mobile, and document remediation Support for VPAT (Voluntary Product Accessibility Template) creation Expert consulting and training solutions to help teams build sustainable accessibility practices from the ground up. This comprehensive approach makes BarrierBreak the preferred partner for businesses looking to scale their digital accessibility efforts. Gartner subscribers can view the report Gartner Market Guide for Digital Accessibility, 2025 Gartner Disclaimer: Gartner, Market Guide for Digital Accessibility, Brent Stewart, Will Grant, 1 August 2025 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About BarrierBreak BarrierBreak is an accessibility auditing and consulting firm with a team of 300+ people, based out of India with a global footprint - trusted partner to customers in US, Europe, UK, Australia and India to meet accessibility requirements. Our Products A11yInspect & A11yNow make testing easy and assist you to manage your compliance. Our Services of Accessibility Testing, and VPAT & ACR ensure adherence to WCAG, ADA, EAA, Section 508, RPwD Act and more. Whether you have a project or need a dedicated team focusing on accessibility, reach out to us for quality and cost- effective accessibility solutions.
Cision Canada
25 minutes ago
- Cision Canada
Baylin Technologies Receives $735,000 (CAD) Purchase Order from a Middle East Broadcaster for its Advantech Genesis Amplifiers
TORONTO, Aug. 12, 2025 /CNW/ - Baylin Technologies Inc. (TSX: BYL) (OTCQB:BYLTF) ("Baylin" or the "Company") is pleased to announce that its Advantech Wireless Technologies ("Advantech") subsidiary has received a $735,000 purchase order from a Middle East broadcaster for its Genesis amplifiers to be used in a mobile satcom network. Advantech's Genesis solid state amplifiers provide unparalleled reliability. The CAN-Bus operating platform supports component-level diagnostics along with the ability to modify features and operations parameters by remote control. Subsequent phase orders of similar magnitude are anticipated for the near future. Leighton Carroll, Baylin's CEO, said "This is an important milestone in several ways – not just for Advantech, but for Baylin overall. In other words, while the purchase order is terrific, the implications for the future are more meaningful." "The Genesis amplifiers represent new technology architecture, which is replacing older legacy technology. That technology had complicated supply chains – meaning parts ordering and inventory complexity. It also meant that our production team would have to work on different designs and materials, even in the same product family. That led to longer lead times in manufacturing." "Genesis has great performance with more features and resiliency. Importantly, it is also based on a consistent component architecture. This means these products have simplified inventory requirements given this consistency of design. It also means that manufacturing is streamlined, leading to higher efficiency and substantially lower book to bill times on these products." "We have effectively retired two significant legacy product groups and replaced them with better performing products that we can produce more efficiently. We expect this will lead to improving margins for our Satellite business in the coming years." About Baylin Baylin is a leading diversified global wireless technology company. Baylin focuses on research, design, development, manufacturing and sales of passive and active radio-frequency and satellite communications products, and the provision of supporting services. Baylin aspires to exceed its customers' needs and anticipate the direction of the market. For further information, please visit Forward Looking Statements This press release includes forward-looking information and forward-looking statements (together, "forward-looking statements") within the meaning of applicable securities laws. Forward-looking statements are not statements of historical fact. Rather, they are disclosure regarding conditions, developments, events or financial performance that we expect or anticipate may or will occur in the future, including, among other things, information or statements concerning our objectives and strategies to achieve those objectives, statements with respect to management's beliefs, estimates, intentions and plans, and statements concerning anticipated future circumstances, events, expectations, operations, performance or results. Forward-looking statements can be identified generally by the use of forward looking terminology, such as "anticipate", "believe", "could" "should", "would", "estimate", "expect", "forecast", "indicate", "intend", "likely, "may", "outlook", "plan", "potential", "project", "seek", "target", "trend" or "will", or the negative or other variations of these words or other comparable words or phrases, and are intended to identify forward-looking statements, although not all forward-looking statements contain these words. The forward-looking statements in this press release include statements regarding the reliability, superior technology, improved manufacturing efficiencies, better performance and improved margins of Avantech's Genesis amplifiers.. Forward-looking statements are based on certain assumptions and estimates made by us in light of the experience and perception of historical trends, current conditions, expected future developments, including projected growth and sales in passive and active radio frequency and satellite communications products and services, and other factors we believe are appropriate and reasonable in the circumstances, but there can be no assurance that such assumptions and estimates will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including the risk factors discussed in the Company's most recent Annual Information Form, which is available on the Company's profile on SEDAR+ at All the forward-looking statements in this press release are qualified by these cautionary statements and other cautionary statements or factors in this press release. There can be no assurance that the actual results or developments will be realized or, even if substantially realized, will have the expected consequences to, or effects on, the Company. Unless required by applicable securities law, the Company does not intend and does not assume any obligation to update these forward-looking statements.
